Form 4: CRISPR Therapeutics Director Receives Stock Option Grant

Director Ali Behbahani was granted 13,000 stock options in CRISPR Therapeutics AG as part of standard compensation.

Summary

• Director Ali Behbahani received a grant of 13,000 stock options for CRISPR Therapeutics AG (CRSP).
• The options have an exercise price of $51.84 per share.
• The grant date for these options is June 5, 2026.
• The options are set to expire on June 5, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of CRSP common shares.

Future Outlook

The options vest in 12 equal monthly installments, with the final installment vesting by the earlier of the one-year anniversary of the grant or the 2027 Annual Meeting, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level expertise for oversight of complex R&D pipelines.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical compensation packages for directors in mid-cap biotech firms.
• The use of monthly vesting over one year is a standard retention mechanism for board members.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first installment of options on June 30, 2026.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Stock Options, Insider Trading, Biotech